Kobayashi Pharmaceutical Co., Ltd.
4967
Pozycja w akcjach
#4484
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries,... Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Cena akcji
$45.65
Kapitalizacja rynkowa
$3.39B
Zmiana (1 dzień)
-0.40%
Zmiana (1 rok)
30.30%
Kraj
JP
Handel Kobayashi Pharmaceutical Co., Ltd. (4967)
Kategoria
Consumer Defensive
Zyski dla Kobayashi Pharmaceutical Co., Ltd. (4967)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Kobayashi Pharmaceutical Co., Ltd., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Kobayashi Pharmaceutical Co., Ltd. od 2005 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2025 | $23.86M | -73.08% |
| 2024 | $88.62M | -54.65% |
| 2023 | $195.41M | -8.33% |
| 2022 | $213.16M | -11.21% |
| 2021 | $240.08M | -6.94% |
| 2020 | $257.99M | 4.61% |
| 2019 | $246.62M | 6.86% |
| 2018 | $230.79M | 15.20% |
| 2017 | $200.34M | 12.22% |
| 2016 | $178.53M | 6.77% |
| 2015 | $167.22M | -12.30% |
| 2014 | $190.68M | -4.69% |
| 2013 | $200.06M | -16.27% |
| 2012 | $238.92M | 50.28% |
| 2011 | $158.98M | 2.08% |
| 2010 | $155.74M | -5.80% |
| 2009 | $165.34M | 4.35% |
| 2008 | $158.45M | 16.55% |
| 2007 | $135.95M | 14.16% |
| 2006 | $119.09M | -0.17% |
| 2005 | $119.29M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $20.38B | - |
US
|
|
| $9.83B | - |
FR
|
|
| $2.94B | - |
US
|
|
| $1.55B | - |
IN
|
|
| $517.00M | - |
US
|
